Introduction: Hypercholesterol is a high cholesterol level in the blood. Blood cupping therapy is a technique of excreting metabolic waste in the blood through the skin. The study aimed to measure any effect of blood cupping therapy to HDL and LDL cholesterol. Method: It was a Quasi-Experimental study using humans as research subjects. Non random consecutive sampling. Patiens with hypercholesterol after 12 hours of fasting were treated with blood cupping, 9 points. Research subjects were 51 men divided into three groups, the cupping group only consisted of 17 men, the drug group without cupping consisted of 17 men, and the cupping and drug consisted 17 men. Collecting data from third of the groups as pre and post data. The data were analyzed by Mann Whitney, Wilcoxon and Kruskal Wallis. The research took place at the Laboratory of Biochemistry, Universitas Jember. Results: Measurement of HDL cholesterol on the cupping group was pretest=33.03±3.73; posttest=37.58±6.54; p=0.000. The drug group was pretest=33.40±3.18; posttest=33.56±3.50; p=0.788. The cupping and drug group was pretest=34.32±3.38; posttest=37.61±2.01; p=0.002. Kruskal Wallis test on pretest group was 0.534 and on posttest group was 0.002. Measurement of LDL cholesterol on the cupping group was pretest=154.70±39.68; posttest=123.89±41.86; p=0.000. The drug group was pretest=151.24±44.17; posttest=151.24±44.17; p=0.019. The cupping and drug group was pretest=147.48±62.66; posttest=105.57±57.94; p=0.001. Kruskal Wallis test on pretest group was 0.439 and on posttest group was 0.082. This means that there was no difference in the average pretest and posttest LDL levels in the cupping, drug, cupping and drug groups. Conclusion: The intervention of blood cupping therapy can increase HDL cholesterol level, and reduce LDL cholesterol level. Further research needs to be done to measure the potential prevention of atherosclerosis.
Hypercholesterolemia is a high level of cholesterol in the blood. Patients must take anti-cholesterol drugs for a long time, so they are at risk of experiencing side effects from the drug. Apo-B and total cholesterol are indicators of cholesterol levels in the blood. Wet cupping therapy is a method of excreting metabolic waste in the blood through the surface of the skin. The study aims to prove the effect of wet cupping therapy as a complementary therapy to decrease Apolipoprotein-B. Method: This research is Quasy experimental research using humans as research subjects. The dependent variable is Apo-B, and total cholesterol gave wet cupping treatment. Cupping is done twice, 7 points, using a G21 needle. A large sample of 32 people with hypercholesterolemia divided into treatment groups and control groups. The research subjects were selected based on sample inclusion criteria. After 12 hours of fasting and still taking simvastatin, blood was taken through 5ml of the brachial vein. Put into a 2ml purple tube containing EDTA the rest inserted in a red tube. Apo-B measurement using ELISA sandwich method, elabscience reagent, BiopharmaELISA reader tool, in units of ng/ml. Total cholesterol uses the enzymatic colorimetry method, diasys reagent, Biolyzer100 spectrophotometry, in mg/dl units. Data analysis was carried out with the Wilcoxon Signed Ranks Test with a significance level of 5% (α = 0.05), the pre-datacompared with the post data. Results: A significant reduction in Apo-B measurements with p-value 0.000 (α <0.05), SD 42. Conclusion: Intervention of wet cupping therapy can reduce Apo-B levels in the blood. Further research needs to be done to measure the potential for prevention of atherosclerosis.
Hypercholesterolemia is a high level of cholesterol in the blood. Patients must take anti-cholesterol drugs for a long time, so they are at risk of experiencing side effects from the drug. Apo-B and total cholesterol are indicators of cholesterol levels in the blood. Wet cupping therapy is a method of excreting metabolic waste in the blood through the surface of the skin. The study aims to prove the potential of wet cupping therapy as a complementary therapy to reduce Apo-B and total cholesterol. Method: This research is Quasy experimental research using humans as research subjects. The dependent variable is Apo-B, and total cholesterol gave wet cupping treatment. Cupping is done twice, 7 points, using a G21 needle. A large sample of 32 people with hypercholesterolemia divided into treatment groups and control groups. The research subjects were selected based on sample inclusion criteria. After 12 hours of fasting and still taking simvastatin, blood was taken through 5ml of the brachial vein. Put into a 2ml purple tube containing EDTA the rest inserted in a red tube. Apo-B measurement using ELISA sandwich method, elabscience reagent, Biopharma ELISA reader tool, in units of ng/ml. Total cholesterol uses the enzymatic colorimetry method, diasys reagent, Biolyzer100 spectrophotometry, in mg/dl units. Data analysis was carried out with the Wilcoxon Signed Ranks Test with a significance level of 5% (α = 0.05), the predatacompared with the post data. Results: A significant reduction in Apo-B measurements with p-value 0.000 (α <0.05), SD 42. A significant reduction also occurred in the total cholesterol group. Obtained p-value 0.005 (α <0.05) SD 0.23. Conclusion:Intervention of wet cupping therapy can reduce Apo-B levels and total cholesterol in the blood. Further research needs to be done to measure the potential for prevention of atherosclerosis.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.